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Brachial plexus neuropathy is a significant cause of pain and
disability in breast cancer patients. The complicated anatomy of
the plexus and its immediate anatomical relationship to blood and
lymphatic vessels makes this a difficult area to image accurately.
The two major causes of brachial plexopathy in breast cancer
patients are metastatic invasion of and radiation damage to the
plexus (Bagley et al, 1978; Cascino et al, 1983). By far the
commonest is metastatic plexopathy, but differentiation between
the two pathologies (often impossible clinically) is important to
plan treatment optimally. Accurate imaging is also required to
define evaluable disease for monitoring treatment efficacy (again
not always possible clinically). Computerized tomography scan-
ning has been used to assess the brachial plexus (Cooke et al,
1988; Moskovic et al, 1992), but it has several limitations, namely
restriction to imaging in the axial plane and the neurovascular
bundle of the axillary artery and brachial plexus may appear as a
single structure when the administration of contrast medium is
poorly timed (Rapaport et al, 1988). In a series of 46 patients with
proven metastatic plexopathy, 11% of patients had normal CT
scans (Cascino et al, 1983).
Positron emission tomography with F18-fluoro-2-deoxy-D-
glucose has previously been used successfully to detect a wide
range of tumours, including brain, head and neck and lung carci-
nomas as well as lymphomas and soft-tissue sarcomas (Wahl et al,
1994; Okada et al, 1992; Strauss and Conti, 1991; DiChiro, 1986).
The utility of PET in cancer imaging relies on the enhanced
glycolytic rate of malignant cells compared with surrounding
normal tissue, which results in increased uptake of the glucose
analogue FDG into the cancer cells. 18FDG-PET has been used to
image to all known sites of primary and metastatic breast cancer in
a series of 12 patients and, in addition, revealed unsuspected nodal
metastases (Wahl et al, 1991). Furthermore, PET imaging has been
shown to have high specificity in the differentiation between
benign and malignant breast tissue (Avril et al, 1996). To our
knowledge, its use in imaging the brachial plexus has been
reported only once, in three patients with suspected metastatic
plexopathy. Two patients had normal scans and were reported to
have had no symptom progression; the third patient (who had non-
diagnostic CT and MRI imaging) had abnormal FDG uptake in the
symptomatic brachial plexus, and subsequent surgical exploration
confirmed metastatic plexopathy (Wald, 1994). We report here a
pilot study using FDG-PET to image the brachial plexus in 19
breast cancer patients, of whom 17 had a suspected metastatic
aetiology while two had suspected radiation plexopathy. Eleven
patients had concurrent CT scans.
PATIENTS AND METHODS
From August 1993 to September 1996, 19 breast cancer patients
with symptoms/signs referrable to the brachial plexus were
evaluated with 18FDG-PET. In 11 cases CT scanning was also
performed. Only three patients had an MRI scan. In addition, three
patients had follow-up FDG-PET studies after treatment with
chemotherapy to correlate symptom responses with changes in
imaging findings. Table 1 shows the clinical characteristics of the
patients studied, including details of any previous anti-cancer
treatment in the adjuvant or advanced setting. All of the patients
who underwent photon beam irradiation to the plexus prior to
symptoms of plexopathy received radiation doses less than or
equal to 50 Gy (radiation doses and fractionation shown in Table
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Table 1 Clinical and imaging characteristics of patients in study
Age Stage at Previous treatment in Interval between Concurrent disease Symptoms/signs CT scan PET scan
presentation adjuvant/advanced diagnosis and at time of of plexopathy
setting plexopathy (years) plexopathy
44 II Axillary sampling 11 Nil C6/7 sensory loss Normal Normal
Adjuvant DXT to breast/gland proximal/distal (MRI normal)
fields (45 Gy/15) weakness
63 III CT (EFC ´4), MRM 2 Skeletal Axilla/anterior Normal Increased FDG at
and ax. cl. chest wall pain left sternal edge
Tamoxifen/prednisolone
57 III Simple mastectomy 9 Lymphatic Pain, distal Minimal +ve
DXT to breast/gland Skeletal weakness thickening
fields (46 Gy/23) Pulmonary
57 IV Nil Presented with Pleural Pain – +ve
plexopathy Lymphatic
43 I E/b + ax. cl. 5 Nil Distal numbness/ – Normal
DXT to breast weakness (MRI: C6/7 disc
herniation)
46 II Mastectomy/ax. cl. 1 Nil Proximal pain – Normal
CT (EFC ´ 6)
DXT scf/upper
axillary chain
Tamoxifen
30 II E/b + DXT to 6 Nil Pain, depressed Minimal +ve (follow-up
breast/gland fields biceps/triceps thickening PET after doxorubicin
MRM (same side) reflexes normal)
+ ax. cl. 4 years later Good symptom response
Adjuvant CMF and tamoxifen
62 I Wide excision and 3 Pulmonary Pain, all reflexes – +ve
ax. cl., DXT to breast Lymphatic depressed
Tamoxifen
73 II E/b and ax. cl. 3 Lymphatic C5–7 numbness Axillary +ve
DXT to breast proximal/distal mass
Tamoxifen weakness
DXT for R scf recurrence
(2 years after diagnosis)
27 I E/b + R ax. cl. 8 Breast mass Pain, distal normal +ve (follow-up
L. axillary recurrence weakness PET unchanged
L. ax. cl. and CT (CMF+EFC) after CMF)
49 I Partial mastectomy 22 Lymphatic (FNA+ve) Dysaesthesiae, distal – +ve
and ax. cl., DXT to breast Pleural weakness
Skeletal Horners syndrome
47 III CT (EFC ´ 4) 2 Lymphatic Pain, distal Axillary +ve
Mastectomy and weakness mass
ax. cl., tamoxifen
36 II E/b and ax. cl., CT (CMF) 2 Lymphatic Pain, Normal +ve
DXT to breast sensory loss
Tamoxifen
44 I E/b and DXT 9 Pulmonary Pain (axilla) – +ve (follow-up
to breast and gland Lymphatic PET after EFC normal).
fields Skeletal Good symptom response
51 I MRM and ax. cl. 3 Anterior axillary Distal sensory loss Normal +ve
Tamoxifen fold mass (FNA +ve)
55 II Mastectomy 4 Lymphatic Pain, distal weakness– +ve
and ax. cl. CT (CMF) Pulmonary
Tamoxifen
48 II Simple mastectomy 10 Nil Distal weakness, – Normal (MRI
and axillary node biopsy distal sensory loss, normal)
DXT axilla and scf (45 Gy/15) absent reflexes
42 II E/b and ax. cl. 2 Lymphatic Distal weakness, Axillary +ve
CT (CMF ´6) pain mass
DXT breast
50 II E/b and ax. cl. 3¢ Skeletal Pain, sensory loss Minimal +ve
CT (CMF ´6) Lymphatic thickening
DXT breast
Tamoxifen
CT, chemotherapy; DXT, radiotherapy; MRM, modified radical mastectomy; ax. cl., axillary clearance; E/b, excison biopsy; scf, supraclavicular fossa. CMF:
cyclophosphamide (100 mg m–2 orally days 1–14), methotrexate (40 mg m–2 intravenously days 1 and 8) and 5-fluorouracil (600 mg m–2 intravenously days 1
and 8). EFC: epirubicin (70 mg m–2 intravenously every 3 weeks), cyclophosphamide (700 mg m–2 intravenously every 3 weeks) and 5-fluorouracil (700 mg m–2
intravenously every 3 weeks). Where indicated MRI was performed. Unless indicated otherwise, DXT was 50 Gy in 25 fractions to breast (and gland fields
where indicated with midplane dose for axilla defined as 50 Gy).480 A Ahmad et al
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1). Only two patients received more than 2.5 Gy per fraction (both
had radiation-induced brachial plexopathy). In all cases in which
both chemotherapy and radiotherapy were administered in the
adjuvant setting, chemotherapy was completed at least 3 weeks
before irradiation was started.
Fluoride-18 was produced in a Siemens RDS cyclotron by
proton bombardment of a high-pressure water target. FDG was
synthesized by the method of nucleophilic substitution of a
precursor by 18F. All PET scans were performed after a 6-h fast
using an ECAT 951 body scanner (Siemens CTI, Knoxville, TN,
USA). Thirty-one slices are produced over a 10.6-cm axial field of
view. Transmission images were acquired initially using rotating
Ge68 rod sources and were later used for attenuation correction in
image reconstruction. Two adjacent emission images of 20 min
duration each were acquired 45 min after injection of 250 MBq of
FDG, commencing at the level of the clavicle to include the
brachial plexus and axillae. The complete set of image planes were
reconstructed by filtered back-projection using a Hann filter with a
cut-off value of 0.4 ´ Nyquist frequency. A three-point smooth
with 3.5 Gaussian width was applied in the axillary direction to
obtain a single dataset with a final spatial resolution of 10 mm in
all three orthogonal directions. CT scans were performed from C5
to the level of the arch of the aorta. Contiguous 5-mm slices were
obtained using a Phillips SR7000 scanner with the patients￿ arms
by their side. Intravenous contrast was not administered.
RESULTS
Of the 19 patients referred for PET study, 14 had abnormal uptake of
18FDG in the region of the symptomatic brachial plexus. Four
patients had normal PET studies and one had increased FDG uptake
at the left sternal edge, which accounted for her symptoms. CT scans
were performed in 9 of the 14 patients who had positive brachial
plexus PET studies; six of these were either normal or showed no
clear evidence of recurrent disease, while three CTs demonstrated
unequivocal brachial plexus involvement. These results are best
interpreted when divided into the four following groups.
1 Positive PET and CT scans: three patients
All three CT scans revealed axillary masses. In one case there was
clear confluent extension around the plexus, whereas in the other
two there was no evidence of brachial plexus infiltration with
preservation of the fat planes around the plexus. PET study
showed clear infiltration along the plexus in two cases as well as
sites of focal uptake in each axilla (all three cases), probably corre-
sponding to the masses on CT scan (Figure 1). It is important to
note that CT in one of the above cases also revealed multiple lung
and mediastinal nodal metastases, which were confirmed as areas
of increased FDG uptake on PET study.
2 Positive PET, negative CT scans: seven patients
Six of the seven patients had increased FDG uptake along the
plexus on the symptomatic side; in three cases CT scanning
A
B
Figure 1 (A) CT and (B) transaxial FDG-PET scan of a patient with
symptoms and signs of a left brachial plexopathy. The CT scan shows a
discrete left axillary mass that can be seen as an area of increased FDG
uptake on the PET image
A
B
Figure 2 (A) CT and (B) coronal FDG-PET scan from a patient with
symptoms and signs of a left brachial plexopathy. CT scan of the left axilla
shows no evidence of brachial plexus infiltration with preservation of the fat
planes. Coronal PET image reveals marked FDG uptake along the left
brachial plexus (arrow 1), both supraclavicular fossae (arrow 2 for right
supraclavicular fossa) and the mediastinum (arrow 3)Positron emission tomography in brachial plexopathy 481
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revealed minimal increased thickness of the abnormal plexus in
comparision with the other asymptomatic side. The remaining
three CT scans were normal (Figure 2).
Three patients proceeded to radiotherapy; two had mild
symptom response (less shooting pain/numbness), though both
were also receiving concurrent analgesia; the third had no signifi-
cant symptom response. The other three patients received pallia-
tive chemotherapy (CMF in two cases, doxorubicin in one case) —
one had no symptom benefit (although there was objective
evidence of response with a decrease in the size of an ipsilateral
supraclavicular lymph node) — the remaining two patients had
more significant symptom responses and repeat PET study in these
cases revealed complete resolution of FDG brachial plexus uptake
in one case and no change in the other.
The seventh patient in this group had complained of left chest
wall and axillary pain, which was associated with weakness of her
fingers during the episodes of pain. She had mild thumb abduction
weakness on examination. CT scan of her left axilla and brachial
plexus was normal. PET scan revealed increased FDG uptake at
the left sternal edge adjacent to the attachment of the sixth rib but
no evidence of brachial plexus uptake; palliative radiotherapy was
administered with complete resolution of chest and axillary pain.
There has been no progression of left arm symptoms for 2 years.
3 Positive PET, no CT scans five patients
All five patients had clinical evidence of either locoregional
(supraclavicular fossa or axillary node) or distant recurrence (new
pleural effusion) as well as brachial plexopathy. Three of the
above received chemotherapy (one received a combination of
epirubicin, cyclophosphamide and 5-fluorouracil, the other two
received doxorubicin) with good subjective and objective response
with follow-up FDG-PET in one case returning to normal. The
fourth patient has more recently started chemotherapy (epirubicin)
to treat plexopathy and distant metastatic disease; the fifth patient
underwent local radiotherapy followed by systemic treatment with
tamoxifen and experienced an initial improvement in hand
strength as well as a response in her metastatic bone disease (fall
of alkaline phosphatase to normal). Figure 3 shows serial coronal
PET images from one of the above patients who developed symp-
toms and signs of a right brachial plexopathy.
4 Negative PET scans: four patients
The first patient complained of left upper arm pain 1 year after
completing radiotherapy to her left supraclavicular fossa and
upper axillary chain for local recurrence. There were no positive
neurological signs and PET study was normal. Her symptoms have
since completely resolved.
The second patient with a normal PET study had cervical disc
herniation visible on MRI that accounted for her symptoms (MRI
of brachial plexus was normal).
The third patient had a right simple mastectomy and low axillary
clearance in 1979 for a 1.5 cm infiltrating intraductal carcinoma
with one positive axillary lymph node. She then underwent post-
operative radiotherapy with semi-opposed fields on a cobalt-60
teletherapy unit to a total tumour dose of 45 Gy in 15 fractions over
3 weeks. She remained well for 11 years, after which she developed
numbness in the C6/7 dermatome. CT scanning and MRI revealed
no evidence of recurrence. Over the next 4 years she developed
progressive weakness of her right arm and hand with marked
wasting of deltoid, pectoralis major and supraspinatus. Sensory
signs remained confined to the lower dermatome and the triceps
jerk was absent. Repeat MRI scan was normal, as was chest radiog-
raphy, bone scan and abdominal ultrasonography. Based on the
history, physical findings and lack of evidence of disease recur-
rence (locoregionally and distant sites) over 5 years, this patient
almost certainly has radiation-induced brachial plexopathy. FDG-
PET study in this case was also normal. The fourth patient in this
group presented in 1979 with two lumps in the left breast (2.5 cm
and 2 cm). Excision biopsy confirmed infiltrating carcinoma in
both lesions extending into fat and perineural spaces. She
proceeded to left simple mastectomy and axillary node biopsy (one
axillary node contained metastatic carcinoma). Post-operatively
she underwent irradiation to the left axilla and supraclavicular fossa
with semiopposed fields on a cobalt-60 teletherapy unit (45 Gy in
15 fractions). She remained well for 10 years, when she developed
paraesthesiae in her left hand. She had left carpal tunnel decom-
pression in 1991 without any improvement. Numbness in the
medial aspect of the left hand developed and electromyography
(EMG) suggested a diffuse brachial plexus lesion. MRI scanning
showed no evidence of recurrence and the brachial plexus appeared
normal. There was, and never has been, any clinical or radiological
(liver ultrasound, chest radiography and bone scan) evidence of
disease recurrence elsewhere. Progression of plexopathy over
recent years has resulted in marked distal weakness and wasting,
loss of biceps/triceps/supinator reflexes and numbness in C8
dermatome. FDG-PET study in this case was also normal.
DISCUSSION
This study demonstrates the feasibility of imaging the brachial
plexus in cancer patients with intravenously injected 18FDG and a
PET imaging device. CT has been used to study the brachial
plexus (Cascino et al, 1983; Moskovic et al, 1992), but it is clear
that it can be unreliable in this area. Data presented here show that
six patients who had metastatic plexopathy (presence of concur-
rent locoregional disease or subsequent response to anti-cancer
treatment) had either normal CT scans or the appearance of
minimal thickening of the plexus. It is possible that this latter
appearance may be related to previous axillary nodal dissection or
radiotherapy. The three patients with positive CT scans had clearly
delineated axillary masses, which is the commonest imaging
finding in cases in which CT is helpful (Cascino et al, 1983;
Thyagarajan et al, 1995). However, in one of the above cases, the
appearance of the brachial plexus was normal, whereas FDG-PET
showed clear uptake along the plexus. Furthermore, CT is not able
to differentiate tumour infiltration from radiation fibrosis (Cascino
et al, 1983). MRI has been claimed to be the test of choice in eval-
uating brachial plexopathy (Sherrier and Sostman, 1993). Its supe-
riority to CT scanning relates to its multiplanar capability (axial,
coronal and sagittal planes) and ability to differentiate more accu-
rately nerves from surrounding vessels and soft tissues (Rapaport
Figure 3 Sequence of coronal PET images from a patient with symptoms
and signs of a right brachial plexopathy showing uptake of FDG in the right
brachial plexus, bilateral cervical lymph nodes, mediastinum, hila and left
axilla482 A Ahmad et al
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et al, 1988; Sherrier and Sostman, 1993). Review of the literature
suggests that there is no doubt that MRI can delineate both the
normal and abnormal anatomy of the brachial plexus in more
detail than can CT scan (Ahern et al, 1991; Sherrier and Sostman,
1993; Panasci et al, 1995). Again, the presence of a discrete mass
in relation to the plexus is the commonest finding in patients with
metastatic plexopathy, although similar findings have been
reported in radiation plexopathy patients (Thyagaragan et al,
1995). Indeed, in the largest published study to date on MRI
imaging of brachial plexopathy in cancer patients, the overall MRI
diagnosis was in disagreement with the clinicopathological diag-
nosis in 21% of patients (Thyagaragan et al, 1995). Regarding the
distinction between radiation and neoplastic plexopathy using
MRI, there are encouraging data that tumour recurrence has a
higher signal intensity than radiation fibrosis on T2-weighted
images (Glazer et al, 1985; Rapaport et al, 1988), although other
authors have reported increased T2 signal in both metastatic and
radiation plexopathy patients (Thyagaragan et al, 1995).
The results presented here suggest that FDG-PET is a useful
imaging technique to study the brachial plexus in breast cancer
patients (especially when CT has been unhelpful) and that it may
be useful to monitor treatment efficacy (post-treatment scans in
three cases revealed resolution of uptake in two and no change in
the third). Indeed, PET has previously been reported to be of use in
monitoring treatment responses in breast cancer patients
(Huovinen et al, 1993; Wahl et al, 1993). Larger studies correlating
changes in FDG-PET appearances of the brachial plexus with
changes in clinical findings during and after treatment are
required, however. The data here are insufficient to suggest
unequivocally that FDG-PET may be useful in distinguishing
neoplastic and radiation plexopathy as there were only two clear-
cut cases of the latter. Of the four patients who had increased FDG
uptake in axillae that had previously been treated with radio-
therapy, two had good clinical and radiological responses to
chemotherapy, a third patient had evidence of new and active
locoregional disease and the fourth had an axillary mass visible on
CT scan. In addition, one of the patients who responded to
chemotherapy also had distant sites of FDG uptake that resolved
post treatment. However, it is encouraging that, in the two patients
whose most likely diagnosis was radiation-induced plexus
damage, the FDG-PET study was normal, suggesting an aetiology
distinct from carcinoma or inflammation. The underlying patho-
logical process in radiation plexus damage is chronic fibrosis, and
it would seem unlikely that significant increased FDG uptake will
occur in such areas. Indeed, FDG-PET is being used to differen-
tiate recurrent tumour from post-operative/radiotherapy scar tissue
in the pelvis and brain (Patronas et al, 1982; DiChiro et al, 1988;
Sigurdson and Cohen, 1991). If it is shown to be similarly reliable
in the axilla then FDG-PET may be useful in resolving this diag-
nostic dilemma.
CONCLUSION
18FDG-PET scanning is a useful tool in the evaluation of patients
with suspected metastatic plexopathy, particularly if other imaging
studies are normal. As a result of its cost and limited availability at
present, its routine use to investigate the brachial plexus cannot be
recommended as yet until comparision is made with MRI, the
investigation of choice at present, and correlated with clinical find-
ings before and after treatment.
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